{
    "id": 7560,
    "fullName": "FLT3 F691L",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 F691L lies within the protein kinase domain of the Flt3 protein (PMID: 23430109). F691L has been demonstrated to promote secondary drug resistance in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 23430109, PMID: 19318574, PMID: 22504184, PMID: 29187377), but is not transforming in cell culture and therefore, is predicted to have no effect on Flt3 protein function (PMID: 30651561).",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3028,
                    "pubMedId": 23430109,
                    "title": "Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23430109"
                },
                {
                    "id": 11567,
                    "pubMedId": 29187377,
                    "title": "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29187377"
                },
                {
                    "id": 3029,
                    "pubMedId": 19318574,
                    "title": "FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19318574"
                },
                {
                    "id": 11566,
                    "pubMedId": 22504184,
                    "title": "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22504184"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "F691L",
    "createDate": "06/12/2015",
    "updateDate": "06/18/2019",
    "referenceTranscriptCoordinates": {
        "id": 144492,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28027224A>G",
        "cDna": "c.2071T>C",
        "protein": "p.F691L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9251,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9279,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 5016,
                "therapyName": "MRX-2843",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7187,
                    "pubMedId": 27158668,
                    "title": "The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27158668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13374,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 F691L were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 2616,
                "therapyName": "G-749",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11044,
                    "pubMedId": 22864397,
                    "title": "The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22864397"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17973,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Quizartinib (AC220)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17977,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Ayvakit (avapritinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4790,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17975,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17974,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4789,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9431,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 5016,
                "therapyName": "MRX-2843",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7187,
                    "pubMedId": 27158668,
                    "title": "The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27158668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11089,
                    "pubMedId": null,
                    "title": "Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.",
                    "url": "http://www.bloodjournal.org/content/114/22/3776?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3 internal tandem duplication (ITD) and FLT3 F691L demonstrated sensitivity to LAM-003 treatment in culture (PMID: 31751472).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 7362,
                "therapyName": "LAM-003",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17544,
                    "pubMedId": 31751472,
                    "title": "LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31751472"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17972,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Crenolanib-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14248,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/F691L compound mutations (PMID: 29187377).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 7085,
                "therapyName": "FF-10101",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11567,
                    "pubMedId": 29187377,
                    "title": "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29187377"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6462,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5604,
                    "pubMedId": 26822154,
                    "title": "The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26822154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17976,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9286,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CG'806 inhibited FLT3 downstream signaling, resulted in growth inhibition in leukemia cells expressing FLT3 exon 14 insertion (ITD) mutation and F691L in culture (Clin Cancer Res 2017; 23(24_Suppl):Abstract nr 25).",
            "molecularProfile": {
                "id": 19129,
                "profileName": "FLT3 exon 14 ins FLT3 F691L"
            },
            "therapy": {
                "id": 7038,
                "therapyName": "CG-806",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14597,
                    "pubMedId": null,
                    "title": "CG?806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3",
                    "url": "http://clincancerres.aacrjournals.org/content/23/24_Supplement/25"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4808,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19276,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R834Q"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4810,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19278,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835E"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4825,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19280,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835H"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4828,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19282,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835N"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4832,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19283,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839G"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4838,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19286,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842C"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4839,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19287,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842H"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19292,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835G"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4806,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19294,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D698N"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4830,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19297,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839A"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4835,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19302,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839N"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4845,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19306,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 G846R"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4802,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19311,
                "profileName": "FLT3 exon 14 ins FLT3 M664I FLT3 F691L"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19314,
                "profileName": "FLT3 exon 14 ins FLT3 N676S FLT3 F691L"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4837,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19317,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 N841K"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4843,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19320,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R845G"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4841,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19324,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842S"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4829,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19343,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835Y"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Flt3 F691L, indicating F691L as a resistance mutation since D835Y was sensitive alone (PMID: 30651561).",
            "molecularProfile": {
                "id": 32516,
                "profileName": "FLT3 F691L FLT3 D835Y"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7440,
            "profileName": "FLT3 F691L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19129,
            "profileName": "FLT3 exon 14 ins FLT3 F691L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19276,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R834Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19278,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19280,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19282,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19283,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19286,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19287,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19292,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19294,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D698N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19297,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19302,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D839N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19306,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 G846R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19311,
            "profileName": "FLT3 exon 14 ins FLT3 M664I FLT3 F691L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19314,
            "profileName": "FLT3 exon 14 ins FLT3 N676S FLT3 F691L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19317,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 N841K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19320,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 R845G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19324,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 Y842S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19343,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32516,
            "profileName": "FLT3 F691L FLT3 D835Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144493,
            "transcript": "XM_011535015",
            "gDna": "chr13:g.28027167A>G",
            "cDna": "c.2071T>C",
            "protein": "p.F691L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 144492,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28027224A>G",
            "cDna": "c.2071T>C",
            "protein": "p.F691L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}